A Novel Panel of Blood-Based Micrornas Capable of Discrimination Between Benign Breast Disease and Breast Cancer at Early Stages

A Novel Panel of Blood-Based Micrornas Capable of Discrimination Between Benign Breast Disease and Breast Cancer at Early Stages Publisher Pubmed

Sadeghi H¹ ; Kamal A² ; Ahmadi M¹ ; Najafi H¹ ; Sharifi Zarchi A³ ; Haddad P⁴ ; Shayestehpour B¹ ; Kamkar L⁵ ; Salamati M⁶ ; Geranpayeh L⁷ ; Lashkari M⁴ ; Totonchi M¹

Show Affiliations

1. Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, Tehran, Acecr, Iran
2. Department of Clinical Bioinformatics, Saarland University, Saarbrucken, Germany
3. Department of Computer Engineering, Sharif University of Technology, Tehran, Iran
4. Radiation Oncology Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
6. Department of Reproductive Imaging, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, Tehran, Acecr, Iran
7. Department of Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: RNA Biology Published:2021

Abstract

Breast cancer (BC) as a leading cause of cancer death among women, exhibits a wide range of genetic heterogeneity in affected individuals. Satisfactory management of BC depends on early diagnosis and proper monitoring of patients’ response to therapy. In this study, we aimed to assess the relation between the expression patterns of blood-based microRNAs (miRNAs) with demographic characteristics of the patients with BC in an attempt to find novel diagnostic markers for BC with acceptable precision in clinical applications. To this end, we performed comprehensive statistical analysis of the data of the Cancer Genome Atlas (TCGA) database and the blood miRNome dataset (GSE31309). As a result, 21 miRNAs were selected for experimental verification by quantitative RT-PCR on blood samples of 70 BC patients and 60 normal individuals (without any lesions or benign breast diseases). Statistical one-way ANOVA revealed no significant difference in the blood levels of the selected miRNAs in BC patients compared to any lesions or benign breast diseases. However, the multi-marker panel consisting of hsa-miR-106b-5p, −126-3p, −140-3p, −193a-5p, and −10b-5p could detect early-stages of BC with 0.79 sensitivity, 0.86 specificity and 0.82 accuracy. Furthermore, this multi-marker panel showed the potential of detecting benign breast diseases from BC patients with 0.67 sensitivity, 0.80 specificity, and 0.74 accuracy. In conclusion, these data indicate that the present panel might be considered an asset in detecting benign breast disease and BC. © 2021 Informa UK Limited, trading as Taylor & Francis Group.

Related Docs

View other Related Docs

1. Small Molecules With Huge Impacts: The Role of Mirna-Regulated Pi3k Pathway in Human Malignancies, Molecular Biology Reports (2021)

2. Exosomes and Micrornas in Biomedical Science, Synthesis Lectures on Biomedical Engineering (2022)

3. Microrna a New Gate in Cancer and Human Disease: A Review, Journal of Biological Sciences (2017)

4. Micrornas in Breast Cancer: Roles, Functions, and Mechanism of Actions, Journal of Cellular Physiology (2020)

5. Potential Roles of Endothelial Cells-Related Non-Coding Rnas in Cardiovascular Diseases, Pathology Research and Practice (2023)

6. Microrna-155 and Its Exosomal Form: Small Pieces in the Gastrointestinal Cancers Puzzle, Cell Biology and Toxicology (2024)

7. Ectopic Expression of Mirna-21 and Mirna-205 in Non-Small Cell Lung Cancer, International Journal of Cancer Management (2019)

8. The Potential for Circulating Micrornas in the Diagnosis of Myocardial Infarction: A Novel Approach to Disease Diagnosis and Treatment, Current Pharmaceutical Design (2016)

Experts (# of related papers)

View all Related Experts

Hamid Reza Mirzaei (2)

Pantea Izadi (1)

Style	Citing Format
MLA	Sadeghi H, et al.. "A Novel Panel of Blood-Based Micrornas Capable of Discrimination Between Benign Breast Disease and Breast Cancer at Early Stages." RNA Biology, vol. 18, no. S2, 2021, pp. 747-756.
APA	Sadeghi H, Kamal A, Ahmadi M, Najafi H, Sharifi Zarchi A, Haddad P, Shayestehpour B, Kamkar L, Salamati M, Geranpayeh L, Lashkari M, Totonchi M (2021). A Novel Panel of Blood-Based Micrornas Capable of Discrimination Between Benign Breast Disease and Breast Cancer at Early Stages. RNA Biology, 18(S2), 747-756.
Chicago	Sadeghi H, Kamal A, Ahmadi M, Najafi H, Sharifi Zarchi A, Haddad P, Shayestehpour B, et al.. "A Novel Panel of Blood-Based Micrornas Capable of Discrimination Between Benign Breast Disease and Breast Cancer at Early Stages." RNA Biology 18, no. S2 (2021): 747-756.
Harvard	Sadeghi H et al. (2021) 'A Novel Panel of Blood-Based Micrornas Capable of Discrimination Between Benign Breast Disease and Breast Cancer at Early Stages', RNA Biology, 18(S2), pp. 747-756.
Vancouver	Sadeghi H, Kamal A, Ahmadi M, Najafi H, Sharifi Zarchi A, Haddad P, et al.. A Novel Panel of Blood-Based Micrornas Capable of Discrimination Between Benign Breast Disease and Breast Cancer at Early Stages. RNA Biology. 2021;18(S2):747-756.
BibTex	@article{ author = {Sadeghi H and Kamal A and Ahmadi M and Najafi H and Sharifi Zarchi A and Haddad P and Shayestehpour B and Kamkar L and Salamati M and Geranpayeh L and Lashkari M and Totonchi M}, title = {A Novel Panel of Blood-Based Micrornas Capable of Discrimination Between Benign Breast Disease and Breast Cancer at Early Stages}, journal = {RNA Biology}, volume = {18}, number = {S2}, pages = {747-756}, year = {2021} }
RIS	TY - JOUR AU - Sadeghi H AU - Kamal A AU - Ahmadi M AU - Najafi H AU - Sharifi Zarchi A AU - Haddad P AU - Shayestehpour B AU - Kamkar L AU - Salamati M AU - Geranpayeh L AU - Lashkari M AU - Totonchi M TI - A Novel Panel of Blood-Based Micrornas Capable of Discrimination Between Benign Breast Disease and Breast Cancer at Early Stages JO - RNA Biology VL - 18 IS - S2 SP - 747 EP - 756 PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract